Fibroblast growth factor therapies in biliary tract cancers: current and future state [0.03%]
胆道癌的成纤维细胞生长因子治疗：现状与未来趋势
Teerada Siripoon,Conor O&#x;Donnell,Zhaohui Jin et al.
Teerada Siripoon et al.
Introduction: Cholangiocarcinoma is the rare and aggressive tumor with poor prognosis and limited therapeutic options. Recently, there have been promising developments in molecular targeted therapies for patients followin...
Sankalp Arora,Pankit Vachhani,Prithviraj Bose
Sankalp Arora
Introduction: Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, and organomegaly. Four JAK inhibitors are US-FDA approved for treatment of MF. While these drugs...
Olga A Koroleva,Alexander V Kurkin,Alexander A Shtil
Olga A Koroleva
Introduction: The Hippo signaling governs the expression of genes critically important for cell proliferation and survival. The components of this pathway are considered antitumor drug targets. However, the design of Hipp...
Hepatic encephalopathy: experimental drugs in development and therapeutic potential [0.03%]
肝性脑病：在研药物及其治疗潜力
Antonio Gil-Gómez,Rocío Muñoz-Hernández,Filomeno Martínez et al.
Antonio Gil-Gómez et al.
Introduction: Hepatic encephalopathy (HE) presents a complex pathophysiology, creating multiple potential treatment avenues. This review covers current and emerging treatments for HE. ...
The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke [0.03%]
QHRD106首次人体研究显示其可安全有效地作为缺血性卒中的长效激肽释放酶药物以改善预后
Lei Huang,Runbin Sun,Hengwen Song et al.
Lei Huang et al.
Background: This study assessed the pharmacokinetics (PK), pharmacodynamics (PD) and safety of QHRD106, and made a comparison with urinary kallindinogenase (UKN) in healthy volunteers. ...
Promising selective progesterone receptor modulators: what's new in female contraception? [0.03%]
新一代避孕药：孕激素受体调节剂的研究进展
Anita Nelson,Marit Pearlman Shapiro
Anita Nelson
Introduction: Selective progesterone receptor modulators (SPRMs), such as mifepristone and ulipristal acetate (UPA), have demonstrated high efficacy and safety as single-dose treatments for medication abortion and emergen...
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer [0.03%]
靶向关键因子FAK：联合使用FAK抑制剂和化疗药物治疗耐药性非小细胞肺癌的潜在疗效
Emma Geijerman,Francesca Terrana,Godefridus J Peters et al.
Emma Geijerman et al.
Introduction: NSCLC is the leading cause of cancer-related deaths globally, with a low survival rate primarily due to NSCLC frequently becoming chemoresistant. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase...
Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan as a novel treatment strategy to alleviate IgA nephropathy [0.03%]
应用斯帕森坦联合阻断内皮素受体A和血管紧张素II受体I作为治疗IgA肾病的新策略
Hajime Nagasawa,Hitoshi Suzuki,Seiji Ueda et al.
Hajime Nagasawa et al.
Introduction: Although immunoglobulin A nephropathy (IgAN) had been discovered more than 50 years ago, 30-40% of IgAN patients still have primary glomerular disease that progresses to end-stage renal disease. However, var...
Management of inflammaging in kidney diseases: focusing on the current investigational drugs [0.03%]
炎症性衰老在肾脏疾病中的管理：重点关注当前研究性药物
Vishwadeep Shelke,Neha Dagar,Maciej Lech et al.
Vishwadeep Shelke et al.
Introduction: To improve kidney disease treatments, it is crucial to understand how inflammaging affects patients´ longevity. We could potentially slow down kidney disease progression and enhance longevity by targeting s...
Protein phosphatase 2A activators under investigation for smoking-related chronic obstructive pulmonary disease and related disorders [0.03%]
用于与吸烟相关慢性阻塞性肺疾病和相关疾病的蛋白磷酸酶2A活化剂的研究
Sabina Antoniu,Setfan Rascu
Sabina Antoniu
Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by progressive inflammation during therapy. Cystic fibrosis (CF), alpha-one antitrypsin deficiency (AATD), and non-CF bronchiectasis are also chr...